metabolic research raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-12-24 and is reviewed periodically as new material appears.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form; may appear as cake |
| Solubility class | Water-soluble | Often reconstituted in aqueous buffer |
| Typical storage temperature | −20 °C or below | Protect from light and moisture |
| Typical analytical method | RP-HPLC and mass spectrometry | Used for purity and identity |
| Common synonyms | AOD-9604; AOD9604; hGH fragment 176-191 | Research name and fragment description |
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
Neoepitopes of Type V collagen have shown to be a useful noninvasive serum biomarker for assessing fibrotic progression and resolution in experimental hepatic fibrosis. Type V Collagens isoform which contains the α3(V) chain is involved in mediating pancreatic islet cell functions. Type V Collagens will arrange with Type I Collagen and form heterotypic fibrils in the skin dermis and cornea. Together, Collagen V and Collagen I acts as a dominant regulator of collagen fibrillogenesis. Type V Collagens interacts with matrix collagens and structural proteins. This interaction improves structural integrity to tissue scaffolds. Harmful roles that Type V collagen can play in the body.
The American IFR (Integral Fast Reactor) can also be operated in an incineration mode, having some advantages in not accumulating the plutonium-242 isotope or the long-lived actinides, which cannot be easily burned except in a fast reactor. Also IFR fuel has a high proportion of burnable isotopes, while in CANDU an inert material is needed to dilute the fuel; this means the IFR can burn a higher fraction of its fuel before needing reprocessing. Most plutonium is produced in research reactors or plutonium production reactors called breeder reactors because they produce more plutonium than they consume fuel; in principle, such reactors make extremely efficient use of natural uranium. In practice, their construction and operation is sufficiently difficult that they are generally only used to produce plutonium. Breeder reactors are generally (but not always) fast reactors, since fast neutrons are somewhat more efficient at plutonium production. Plutonium-239 is more frequently used in nuclear weapons than uranium-235, as it is easier to obtain in quantity capable of criticality. The process of enriching uranium, i.e. increasing the ratio of 235U to 238U to weapons grade, is generally a more lengthy and costly process than the production of plutonium-239 from 238U and subsequent chemical separation.
3 May Drug company Eli Lilly reports that donanemab can slow the pace of Alzheimer's disease by 35%, following a Phase 3 study in human patients. Astronomers using the Gemini South telescope report the first direct evidence of an exoplanet being swallowed by an ancient Sun-like star, a fate that likely awaits the Earth in five billion years. 4 May – Westinghouse Electric's nuclear division announces the AP300, a miniature version of its signature AP1000 nuclear reactor. 5 May – The World Health Organization announces that COVID-19 is no longer considered a global health emergency. 8 May The first infrared image of an asteroid belt outside the Solar System is captured by the James Webb Space Telescope. Three distinct rings of debris are shown to exist around Fomalhaut, a young star 25 light years away. AI successfully identifies people at the highest risk for pancreatic cancer up to three years before diagnosis, using solely the patients' medical records. 10 May A rough draft of the human "pan-genome" is presented, consisting of 47 genomes from a cohort of genetically diverse individuals. This aims to improve medical research by building on the earlier Human Genome Project. Scientists demonstrate with experimental evolution how macroscopic multicellularity could have emerged on Earth. 11 May – The discovery of 62 new moons of Saturn is reported, taking its total confirmed number to 145 and overtaking Jupiter. 15 May The National Institutes of Health begins a Phase 1 trial of an mRNA-based universal influenza vaccine, enrolling 50 volunteers.
Sources: en.wikipedia.org
Nucleic acids, so-called because of their prevalence in cellular nuclei, is the generic name of this family of biopolymers. They are complex, high-molecular-weight biochemical macromolecules that encode genetic information in all living cells and viruses. Their monomers are called nucleotides, and each consists of three components: a nitrogenous heterocyclic base (either a purine or a pyrimidine), a pentose sugar, and a phosphate group.
=== Related drugs === Although described as SNRIs, duloxetine (Cymbalta), venlafaxine (Effexor), and desvenlafaxine (Pristiq) are in fact relatively selective as serotonin reuptake inhibitors (SRIs). They are about at least 10-fold selective for inhibition of serotonin reuptake over norepinephrine reuptake. The selectivity ratios are approximately 1:30 for venlafaxine, 1:10 for duloxetine, and 1:14 for desvenlafaxine. At low doses, these SNRIs act mostly as SSRIs; only at higher doses do they also prominently inhibit norepinephrine reuptake. Milnacipran (Ixel, Savella) and its stereoisomer levomilnacipran (Fetzima) are the only widely marketed SNRIs that inhibit serotonin and norepinephrine to similar degrees, both with ratios close to 1:1. Vilazodone (Viibryd) and vortioxetine (Trintellix) are SRIs that also act as modulators of serotonin receptors and are described as serotonin modulators and stimulators (SMS). Vilazodone is a 5-HT1A receptor partial agonist while vortioxetine is a 5-HT1A receptor agonist and 5-HT3 and 5-HT7 receptor antagonist. Litoxetine (SL 81–0385) and lubazodone (YM-992, YM-35995) are similar drugs that were never marketed. They are SRIs and litoxetine is also a 5-HT3 receptor antagonist while lubazodone is also a 5-HT2A receptor antagonist.
Ridomihan Kersus (リドミハ星人カーサス, Ridomiha Seijin Kāsasu): A plant-themed criminal from Planet Ridomiha who is charged with murder and planetary invasion and is capable of secreting healing liquid from her stalks and producing high-powered water streams capable of slicing objects. Due to their homeworld changing from a water-based planet to a desert-based one, she and her sister Karmia (カーミア, Kāmia) scouted Earth with the intention of stealing its water. After Karmia developed second thoughts, Kersus killed her and framed an alien named Braidy, but Sen-Chan discovers the truth before the Dekarangers delete Kersus with the D-Bazooka. Kersus is voiced by Tomoka Hayashi (林 知花, Hayashi Tomoka), who also portrays her human form. Cuwartlian Dazgonelr (クウォータ星人ダゴネール, Kuwōta Seijin Dagonēru): A childish 10,708-year-old octopus-themed Alienizer from Planet Cuwartl who is charged with turning people into dolls. He manipulates Hikaru, a lonely boy with the power to teleport objects, into helping him before he is deleted by Dekaranger Robo while piloting the Kaijuki Embarns (エンバーンズ, Enbānzu). Dazgonelr is voiced by Yasuhiro Takato (高戸 靖広, Takato Yasuhiro). Zamuzan Sheik (ザムザ星人シェイク, Zamuza Seijin Sheiku): A beetle-themed criminal and bomb manufacturer from Planet Zamuza who was arrested on charges of mass-murder via explosives and imprisoned in the Prison Satellite Prisron (監獄衛生プリズロン, Kangoku Eisei Purizuron).
Sources: en.wikipedia.org
Lyophilized powder is commonly stored at −20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept refrigerated and used within a limited period.
Reversed-phase HPLC and mass spectrometry are standard checks. They confirm peptide purity and molecular mass, but they do not by themselves demonstrate biological activity.
Synthesis, purification, and handling conditions can differ, leading to variations in purity and salt content. Certificates of analysis help, but independent testing is often needed for verification.
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.